newsfilter
← Latest News
GlobeNewswire·

ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

Significant Reduction in Overall Operating Expenses of 41.9% in 2024, Excluding M&A Related Expenses, Compared to 2023 Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys Remain